Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psoriasis drug trial for sensitive areas halted early

NCT ID NCT06042920

Symptom relief Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug deucravacitinib (SOTYKTU) in 130 people with psoriasis on the palms, soles, and genitals. The goal was to see if it improves skin clearance and reduces symptoms. The trial was terminated early, so final results are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deucravacitinib (SOTYKTU)
What this could lead to
If successful, this could provide a new treatment option for hard-to-treat psoriasis on the palms, soles, and genitals.
What could go wrong
The study was terminated early, so results are limited. As a phase 4 trial, safety and efficacy data may not be fully conclusive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

130 people

The number who actually took part.

Started

Oct 2023

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: Inclusion Criteria for Non-Pustular Palmoplantar Psoriasis * Men and women diagnosed with stable plaque psoriasis with involvement of the palm(s)and/or sole(s) for at least 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator. * Moderate-to-severe plaque psoriasis defined as s-PGA score of ≥ 3 on a 5-point scale at both screening visit and Day 1. * Moderate-to-severe non-pustular PP psoriasis, defined as pp-PGA score of ≥ 3 on a 5-pointscale and pp-PASI ≥ 8 at both screening visit and Day 1. * A total maximum of 5 sterile pustules across both palms and soles limited only to psoriatic plaques will be allowed. * Evidence of typical plaque psoriasis outside palms and soles at both screening visit and Day 1. * Deemed by the investigator to be a candidate for phototherapy or systemic therapy. * Failed to respond to, or intolerant of ≥ 1 topical therapy. Inclusion Criteria for Genital Psoriasis * Men and women diagnosed with stable plaque psoriasis with involvement of the genital area for at least 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator. * Moderate-to-severe plaque psoriasis defined as s-PGA score of ≥ 3 on a 5-point scale at both screening visit and Day 1. * Moderate-to-severe GenPs, defined as static Physician's Global Assessment of Genitalia (s-PGA-G) score of ≥ 3 on a 6-point scale at both screening visit and Day 1. * Evidence of typical plaque psoriasis in a non-genital area at both screening visit and Day 1. * Deemed by the investigator to be a candidate for phototherapy or systemic therapy. * Failed to respond to, or intolerant of ≥ 1 topical therapy. Key Exclusion Criteria: Target Disease Exceptions * Has non-plaque psoriasis (for PP pustulosis, PP pustular psoriasis, isolated pustules on palms or soles with or without erythema outside psoriatic plaques, guttate, pustular, erythrodermic, and drug-induced psoriasis) at screening or Day 1. Other protocol-defined inclusion/exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Genital psoriasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

palmoplantar pustulosis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Genital psoriasis Palmoplantar psoriasis

Contacts and locations

Locations

  • Local Institution - 0001

    Winston-Salem, North Carolina, 27157, United States

  • Local Institution - 0002

    New York, New York, 10003, United States

  • Local Institution - 0004

    Santa Monica, California, 90404, United States

  • Local Institution - 0005

    East Windsor, New Jersey, 08520-2505, United States

  • Local Institution - 0007

    Norfolk, Virginia, 23502-3933, United States

  • Local Institution - 0008

    New York, New York, 10075, United States

  • Local Institution - 0009

    Los Angeles, California, 90045-3606, United States

  • Local Institution - 0010

    Houston, Texas, 77004, United States

  • Local Institution - 0012

    Detroit, Michigan, 48202-3141, United States

  • Local Institution - 0015

    Fountain Valley, California, 92708, United States

  • Local Institution - 0029

    Rockville, Maryland, 20850-6243, United States

  • Local Institution - 0033

    Mill Creek, Washington, 98012-1797, United States

  • Local Institution - 0034

    Ciudad Autonoma Buenos Aires, C, C1425DKG, Argentina

  • Local Institution - 0037

    Ciudad Autónoma Buenos Aires, B, C1428DZF, Argentina

  • Local Institution - 0042

    Rosario, S, 2000, Argentina

  • Local Institution - 0043

    Ciudad Autónoma Buenos Aires, B, 1425, Argentina

  • Local Institution - 0050

    Phoenix, Arizona, 85006-2722, United States

  • Local Institution - 0052

    Indianapolis, Indiana, 46250, United States

  • Local Institution - 0053

    Plainfield, Indiana, 46168-2792, United States

  • Local Institution - 0054

    Montreal, Quebec, H2X 2V1, Canada

  • Local Institution - 0055

    Mayfield Heights, Ohio, 44124-4005, United States

  • Local Institution - 0056

    Pittsburgh, Pennsylvania, 15213-3403, United States

  • Local Institution - 0057

    Skokie, Illinois, 60077-1049, United States

  • Local Institution - 0058

    Newmarket, Ontario, L3Y 5G8, Canada

  • Local Institution - 0059

    Québec, Quebec, G1W 4R4, Canada

  • Local Institution - 0060

    Toronto, Ontario, M3B 0A7, Canada

  • Local Institution - 0061

    Saint-Jérôme, Quebec, J7Z 7E2, Canada

  • Local Institution - 0062

    New York, New York, 10128, United States

  • Local Institution - 0064

    Saskatoon, Saskatchewan, S7K 2C1, Canada

  • Local Institution - 0065

    Montreal, Quebec, H1Y 3L1, Canada

  • Local Institution - 0066

    Boardman, Ohio, 44512, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.